

Figure 2. Patient's thyroglobulin and antithyroglobulin antibody levels prior to and throughout selpercatinib therapy. The timing of the two dose reductions are depicted by arrows above the trendline; sustained drop in thyroglobulin levels are seen despite reduced dosing. The horizontal line demarcates when antithyroglobulin antibodies are undetectable (<1.8 IUnits/mL) thus not interfering with the measurement of thyroglobulin levels.

